Avadel Pharmaceuticals plc (AVDL) |
|
15.35 0.26 (1.72%)
|
06-09 14:58 |
|
Open: |
15.14 |
Pre. Close: |
15.09 |
|
High:
|
15.4 |
Low:
|
14.94 |
|
Volume:
|
309,246 |
Market Cap:
|
1,178(M) |
|
|
|
Technical analysis |
as of: 2023-06-09 2:43:24 PM |
|
Short-term rate:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
|
| Target: |
Six months: 18.47 One year: 21.58 |
| Support: |
Support1: 14.12 Support2: 13.07 |
| Resistance: |
Resistance1: 15.81 Resistance2: 18.47 |
| Pivot: |
14.2  |
| Moving Average: |
MA(5): 14.82 MA(20): 14.27
MA(100): 10.4 MA(250): 7.73 |
| MACD: |
MACD(12,26): 0.5 Signal(9): 0.6 |
| Stochastic oscillator: |
%K(14,3): 87.2 %D(3): 83.5 |
| RSI: |
RSI(14): 64.7 |
| 52-week: |
High: 15.81 Low: 2.11 |
| Average Vol(K): |
3-Month: 951 (K) 10-Days: 645 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ AVDL ] has closed below upper band by 5.6%. Bollinger Bands are 15.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
15.21 - 15.27 |
15.27 - 15.32 |
|
Low:
|
14.49 - 14.56 |
14.56 - 14.63 |
|
Close:
|
14.96 - 15.08 |
15.08 - 15.19 |
|
Company Description |
|
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland. |
Headline News |
Fri, 09 Jun 2023
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Receives Consensus ... - MarketBeat
Mon, 05 Jun 2023
Avadel Pharmaceuticals Announces U.S. Commercial Launch of LUMRYZ™ (sodium oxybate) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Adults Living with Narcolepsy - Yahoo Finance
Tue, 30 May 2023
Needham Reiterates Avadel Pharmaceuticals plc - ADR (AVDL) Buy ... - Nasdaq
Sun, 21 May 2023
Independent Director of Avadel Pharmaceuticals Picks Up 8.4% More Stock \ - Simply Wall St
Tue, 16 May 2023
Avadel Pharmaceuticals: Poised for Success in the Pharmaceutical ... - Best Stocks
Thu, 04 May 2023
Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2023 Financial Results - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Drug Manufacturers—Specialty & Generic |
| Shares Out. |
0 (M) |
| Shares Float |
77 (M) |
|
% Held by Insiders
|
5.717e+007 (%) |
|
% Held by Institutions
|
5.2 (%) |
|
Shares Short
|
3,720 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-9.307e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-32.8 |
|
Return on Equity (ttm)
|
-1 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
459.76 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
-2.5 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-66 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
-0.7 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0.03 |
|
Price to Cash Flow
|
-36.99 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
3.35e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
